Blood
Articles in this Issue
Nanoromidepsin, a polymer nanoparticle of the HDAC inhibitor, improves safety and efficacy in models of T-cell lymphoma
Abstract Histone deacetylase inhibitors (HDACis) are valued treatment options for patients with T-cell malignancies. Romidepsin is a selective class I HDACi initially approved for...
Donor-derived CD7 CAR T cells for pediatric and adult relapsed/refractory T-ALL/LBL: a phase 2 trial
Abstract This phase 2 trial assessed CD7 chimeric antigen receptor (CAR) T cells derived from previous transplant or newly HLA-matched donors for relapsed/refractory T-cell acute l...
Atypical hyperlymphocytosis following CAR T-cell infusion
Hijacked helpers: Tr1 cells fuel immune escape in B-ALL
Sweet stuff is dangerous in DLBCL
A structural spotlight on extrinsic Xase complex
The origin, diagnosis, and prognosis of oligomannose-type diffuse large B-cell lymphoma
Abstract The acquisition of N-glycosylation sites that are occupied by oligomannose-type glycans in the immunoglobulin complementarity–determining region (CDR) is an early, clonal,...
Impact of <i>ASXL1</i> at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations
Abstract Genomic profiling in patients with chronic-phase chronic myeloid leukemia (CP-CML) demonstrated somatic variants in blood cancer-related gene variants (CGVs) and rearrange...
Clinical revival of romidepsin with nanoparticles
Cryo-EM structure of the tissue factor/factor VIIa complex with a factor X mimetic reveals a novel allosteric mechanism
Abstract Blood clotting is triggered in hemostasis and thrombosis when the membrane-bound tissue factor (TF)/factor VIIa (FVIIa) complex activates factor X (FX). There are no struc...
On the CHOPping block? Rethinking initial therapy for PMBCL
Marchand T, Lamy T, Loughran TP Jr. A modern view of LGL leukemia. <i>Blood.</i> 2024;144(18):1910-1923.
How can we chop CML with an ASXL1?
Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial
Abstract The IELSG37 trial enrolled 545 patients with primary mediastinal B-cell lymphoma (PMBCL) and demonstrated that consolidation radiotherapy (RT) can be omitted in patients w...
Leukemia escapes immunity by imposing a type 1 regulatory program on neoantigen-specific CD4+ T cells
Abstract The significance of endogenous immune surveillance in acute lymphoblastic leukemia (ALL) remains controversial. Using clinical B-cell ALL samples and a novel mouse model,...
Close V, Close W, Kugler SJ, et al. <i>FBXW7</i> mutations reduce binding of NOTCH1, leading to cleaved NOTCH1 accumulation and target gene activation in CLL. <i>Blood</i> . 2019;133(8):830-839.
The secret to staying young: platelet factor 4
Donor-derived CD7 CAR-T in T-ALL/LBL: promise and pitfalls
Platelet factor 4 regulates hematopoietic stem cell aging
Abstract Hematopoietic stem cells (HSCs) responsible for blood cell production and their bone marrow regulatory niches undergo age-related changes, affecting immune responses and p...